Preclinical evaluation of Amphihevir, a first-in-class clinical Hepatitis C virus NS4B inhibitor.

Tao, Xin; Wang, Ningyu; Wang, Jianfei; Fu, Zhifei; Gu, Zhengxian; Zhang, Yang; Chen, Shuhui; Wang, Lichun; Yu, Luoting.

Afiliação

Tao X; State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.
Wang N; School of Life Science and Engineering, Southwest JiaoTong University, Chengdu, China.
Wang J; WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China.
Fu Z; WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China.
Gu Z; WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China.
Zhang Y; WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China.
Chen S; WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China.
Wang L; State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China.
Yu L; State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China yuluot@scu.edu.cn.

Antimicrob Agents Chemother ; 63(12)2019 09 09.

Article em En | MEDLINE | ID: mdl-31527036

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article